Effect of a disease-modifying antirheumatic drug iguratimod (T-614) on inflammatory cytokine production

Japanese Pharmacology and Therapeutics

Volumn 35, Issue 6, 2007, Pages 551-559

  Yamamoto, Mari ^a   Urata, Noriko ^a   Yamamoto, Tetsuya ^a   Aikawa, Yukihiko ^a   Funaki, Junko ^a   Tanaka, Keiichi ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

DMARD (disease modifying antirheumatic drug); Iguratimod (T 614); Inflammatory cytokines; TNF

Indexed keywords

AMINOTRANSFERASE; CYTOKINE; IGURATIMOD; INDOMETACIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; METHOTREXATE; MONOCYTE CHEMOTACTIC PROTEIN 1; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN;

EID: 34547618430     PISSN: 03863603     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 1990 ; 322 : 1277-89.
2. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 ; 340 : 253-9.
3. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate : a randomized phase III trial. Lancet 1999 ; 354 : 1932-9.
4. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis : a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol 2007 ; 17 : 1-9.
5. Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, et al. Pharmacological studies of the new antiinflammatory agent 3-formylamino-7- methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one, 1st commun., antiinflammatory, analgesic and other related properties. Arzneimittelforschung 1992 ; 42 : 935-44.
6. Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, Abe C. Pharmacological studies on T-614, a novel antiinflammatory agent : Effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/1 mice. Int J Immunother 1993 ; 9 : 69-78.
7. Aikawa Y, Tanuma N, Shin T, Makino S, Tanaka K, Matsumoto Y. A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol 1998 ; 89 : 35-42.
8. Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication : inhibitory effect on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn 1992 ; 15 : 649-55.
9. Tanaka K, Urata N, Mikami M, Ogasawara M, Matsunaga T, Terashima N, et al. Effect of iguratimod and other anti-rheumatic drugs on adenocarcinoma colon 26-induced cachexia in mice. Inflamm Res 2007 ; 56 : 17-23.
10. Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford) 2003 ; 42 : 1365-71.
11. Japanese source
12. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988 ; 48 : 4827-33.
13. Tessier PA, Naccache PH, Clark-Lewis I, Gladue RP, Neote KS, McColl SR. Chemokine networks in vivo : involvement of C-X-C and C-C chemokines in neutrophil extravasation in vivo in response to TNF-alpha. J Immunol 1997 ; 159 : 3595-602.
14. Kuzuhara H, Nishiyama S, Minowa N, Sasaki K, Omoto S. Protective effects of soyasapogenol A on liver injury mediated by immune response in a concanavalin A-induced hepatitis model. Eur J Pharmacol 2000 ; 391 : 175-81.
15. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989 ; 320 : 365-76.
16. Standiford TJ. Anti-inflammatory cytokines and cytokine antagonists. Curr Pharm Des 2000 ; 6 : 633-49.
17. Hirano T. Interleukin 6 and its receptor : ten years later. Int Rev Immunol 1998 ; 16 : 249-84.
18. Brennan FM, Zachariae CO, Chantry D, Larsen CG, Turner M, Maini RN, et al. Detection of interleukin 8 biological activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin 8 mRNA by isolated synovial cells. Eur J Immunol 1990 ; 20 : 2141-4.
19. Villiger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992 ; 149 : 722-7.
20. Spatafora M, Chiappara G, D' Amico D, Volpes D, Melis M, Pace E, et al. Effect of indomethacin on the kinetics of tumour necrosis factor alpha release and tumour necrosis factor alpha gene expression by human blood monocytes. Pharmacol Res 1991 ; 23 : 247-57.
21. Hoffman T, Lee YL, Lizzio EF, Tripathi AK, Jessop JJ, Taplits M, et al. Absence of modulation of monokine production via endogenous cyclooxygenase or 5-lipoxygenase metabolites : MK-886 (3- [1- (4-chlorobenzyl)-3-t-butyl-thio-5- isopropylindol-2-yl]-2,2-dimethyl-propanoic acid), indomethacin, or arachidonate fail to alter immunoreactive interleukin-1 beta, or TNF-alpha production by human monocytes in vitro. Clin Immunol Immunopathol 1991 ; 58 : 399-408.
22. Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol 1995 ; 67 : 305-14.
23. Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol 2001 ; 28 : 2591-6.
24. Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res 2002 ; 51 : 188-94.
25. Seitz M, Loetscher P, Dewald B, Towbin H, Baggiolini M. In vitro modulation of cytokine, cytokine inhibitor, and prostaglandin E release from blood mononuclear cells and synovial fibroblasts by antirheumatic drugs. J Rheumatol 1997 ; 24 : 1471-6.
26. Toyabe S, Seki S, Iiai T, Takeda K, Shirai K, Watanabe H,et al. Requirement of IL-4 and liver NK1 + T cells for concanavalin A-induced hepatic injury in mice. J Immunol 1997 ; 159 : 1537-42.
27. Japanese source
28. Baeuerle PA, Henkel T. Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994 ; 12 : 141-79.
29. Japanese source
30. Tak PP, Firestein GS. NF-kappaB : a key role in inflammatory diseases. J Clin Invest 2001 ; 107 : 7-11.
31. Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, et al. Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med 1999 ; 133 : 566-74.
32. Jeon KI, Jeong JY, Jue DM. Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. J Immunol 2000 ; 164 : 5981-9.
33. Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine : a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998 ; 101 : 1163-74.
34. Japanese source